A sequencing analysis for 1,310 breast cancer patients demonstrated the relevance of CXCL10 and HRD, identifying CXCL10 as biomarker for anti-PD-1/PD-L1 therapy (Shi et al., 2021). This evidence concerns the gene CXCL10 and breast carcinoma.